Innoviva Net Worth
Innoviva Net Worth Breakdown | INVA |
Innoviva Net Worth Analysis
Innoviva's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Innoviva's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Innoviva's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Innoviva's net worth analysis. One common approach is to calculate Innoviva's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Innoviva's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Innoviva's net worth. This approach calculates the present value of Innoviva's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Innoviva's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Innoviva's net worth. This involves comparing Innoviva's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Innoviva's net worth relative to its peers.
Enterprise Value |
|
To determine if Innoviva is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Innoviva's net worth research are outlined below:
| Innoviva generated a negative expected return over the last 90 days | |
| Innoviva is unlikely to experience financial distress in the next 2 years | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Innoviva investors are up 4.7 percent in the past week, but earnings have declined over the last five years |
Innoviva uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Innoviva. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Innoviva's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Innoviva Target Price Consensus
Innoviva target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Innoviva's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 2 | Buy |
Most Innoviva analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Innoviva stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Innoviva, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationInnoviva Target Price Projection
Innoviva's current and average target prices are 18.58 and 19.00, respectively. The current price of Innoviva is the price at which Innoviva is currently trading. On the other hand, Innoviva's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Innoviva Market Quote on 19th of January 2025
Target Price
Analyst Consensus On Innoviva Target Price
Know Innoviva's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Innoviva is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Innoviva backward and forwards among themselves. Innoviva's institutional investor refers to the entity that pools money to purchase Innoviva's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 1.4 M | Goldman Sachs Group Inc | 2024-09-30 | 1.2 M | Bank Of America Corp | 2024-09-30 | 1.1 M | Arrowstreet Capital Limited Partnership | 2024-09-30 | 1.1 M | American Century Companies Inc | 2024-09-30 | 1.1 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1 M | Deutsche Bank Ag | 2024-09-30 | 848.2 K | Charles Schwab Investment Management Inc | 2024-09-30 | 732.3 K | D. E. Shaw & Co Lp | 2024-09-30 | 658.1 K | Blackrock Inc | 2024-09-30 | 9.4 M | Sarissa Capital Management Lp | 2024-09-30 | 7.3 M |
Follow Innoviva's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.16 B.Market Cap |
|
Project Innoviva's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.16 | 0.17 | |
| Return On Capital Employed | 0.13 | 0.14 | |
| Return On Assets | 0.13 | 0.14 | |
| Return On Equity | 0.24 | 0.26 |
When accessing Innoviva's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Innoviva's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Innoviva's profitability and make more informed investment decisions.
Please note, the presentation of Innoviva's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Innoviva's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Innoviva's management manipulating its earnings.
Evaluate Innoviva's management efficiency
Innoviva has return on total asset (ROA) of 0.0937 % which means that it generated a profit of $0.0937 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0997 %, meaning that it created $0.0997 on every $100 dollars invested by stockholders. Innoviva's management efficiency ratios could be used to measure how well Innoviva manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.17. The current year's Return On Capital Employed is expected to grow to 0.14. At present, Innoviva's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 1.1 B, whereas Other Assets are forecasted to decline to about 131.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 9.28 | 9.75 | |
| Tangible Book Value Per Share | 5.87 | 6.16 | |
| Enterprise Value Over EBITDA | 4.72 | 4.95 | |
| Price Book Value Ratio | 1.40 | 1.47 | |
| Enterprise Value Multiple | 4.72 | 4.95 | |
| Price Fair Value | 1.40 | 1.47 | |
| Enterprise Value | 1.9 B | 2 B |
The leadership approach at Innoviva's fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Enterprise Value Revenue 3.8368 | Revenue | Quarterly Revenue Growth 0.331 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Innoviva insiders, such as employees or executives, is commonly permitted as long as it does not rely on Innoviva's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Innoviva insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Innoviva Corporate Filings
F4 | 22nd of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 14th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 9th of May 2024 Other Reports | ViewVerify |
Innoviva Earnings Estimation Breakdown
The calculation of Innoviva's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Innoviva is estimated to be 0.13 with the future projection ranging from a low of 0.13 to a high of 0.13. Please be aware that this consensus of annual earnings estimates for Innoviva is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.13 Lowest | Expected EPS | 0.13 Highest |
Innoviva Earnings Projection Consensus
Suppose the current estimates of Innoviva's value are higher than the current market price of the Innoviva stock. In this case, investors may conclude that Innoviva is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Innoviva's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 1 | 31.24% | 0.02 | 0.13 | 0.81 |
Innoviva Earnings per Share Projection vs Actual
Actual Earning per Share of Innoviva refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Innoviva predict the company's earnings will be in the future. The higher the earnings per share of Innoviva, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Innoviva Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Innoviva, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Innoviva should always be considered in relation to other companies to make a more educated investment decision.Innoviva Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Innoviva's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-04 | 2024-09-30 | 0.26 | 0.02 | -0.24 | 92 | ||
2024-07-31 | 2024-06-30 | 0.24 | -0.55 | -0.79 | 329 | ||
2024-05-08 | 2024-03-31 | 0.17 | 0.46 | 0.29 | 170 | ||
2024-02-29 | 2023-12-31 | 0.23 | 0.76 | 0.53 | 230 | ||
2023-11-01 | 2023-09-30 | 0.27 | 0.98 | 0.71 | 262 | ||
2023-08-02 | 2023-06-30 | 0.26 | 0.02 | -0.24 | 92 | ||
2023-05-09 | 2023-03-31 | 0.23 | 0.42 | 0.19 | 82 | ||
2023-02-28 | 2022-12-31 | 0.23 | -0.98 | -1.21 | 526 | ||
2022-11-09 | 2022-09-30 | 2.24 | 2.8 | 0.56 | 25 | ||
2022-07-27 | 2022-06-30 | 1.93 | 0.05 | -1.88 | 97 | ||
2022-04-27 | 2022-03-31 | 0.44 | 0.35 | -0.09 | 20 | ||
2022-02-09 | 2021-12-31 | 0.41 | 0.14 | -0.27 | 65 | ||
2021-10-27 | 2021-09-30 | 0.43 | 0.9 | 0.47 | 109 | ||
2021-07-28 | 2021-06-30 | 0.29 | 0.9 | 0.61 | 210 | ||
2021-04-28 | 2021-03-31 | -0.01 | 0.84 | 0.85 | 8500 | ||
2021-02-03 | 2020-12-31 | 0.4 | 0.48 | 0.08 | 20 | ||
2020-10-28 | 2020-09-30 | 0.42 | 0.26 | -0.16 | 38 | ||
2020-07-29 | 2020-06-30 | 0.32 | 0.69 | 0.37 | 115 | ||
2020-04-29 | 2020-03-31 | 0.36 | 0.59 | 0.23 | 63 | ||
2020-02-05 | 2019-12-31 | 0.5 | 0.42 | -0.08 | 16 | ||
2019-10-30 | 2019-09-30 | 0.37 | 0.36 | -0.01 | 2 | ||
2019-07-24 | 2019-06-30 | 0.43 | 0.34 | -0.09 | 20 | ||
2019-05-01 | 2019-03-31 | 0.36 | 0.31 | -0.05 | 13 | ||
2019-02-06 | 2018-12-31 | 0.65 | 0.6 | -0.05 | 7 | ||
2018-10-31 | 2018-09-30 | 0.49 | 0.43 | -0.06 | 12 | ||
2018-07-26 | 2018-06-30 | 0.55 | 0.49 | -0.06 | 10 | ||
2018-04-26 | 2018-03-31 | 0.53 | 0.27 | -0.26 | 49 | ||
2018-02-08 | 2017-12-31 | 0.42 | 0.5 | 0.08 | 19 | ||
2017-10-25 | 2017-09-30 | 0.31 | 0.22 | -0.09 | 29 | ||
2017-07-26 | 2017-06-30 | 0.27 | 0.3 | 0.03 | 11 | ||
2017-04-27 | 2017-03-31 | 0.27 | 0.18 | -0.09 | 33 | ||
2017-02-09 | 2016-12-31 | 0.19 | 0.22 | 0.03 | 15 | ||
2016-10-27 | 2016-09-30 | 0.19 | 0.13 | -0.06 | 31 | ||
2016-07-28 | 2016-06-30 | 0.12 | 0.13 | 0.01 | 8 | ||
2016-04-28 | 2016-03-31 | 0.1 | 0.04 | -0.06 | 60 | ||
2016-02-03 | 2015-12-31 | 0.01 | 0.04 | 0.03 | 300 | ||
2015-10-28 | 2015-09-30 | -0.03 | -0.04 | -0.01 | 33 | ||
2015-07-29 | 2015-06-30 | -0.06 | -0.07 | -0.01 | 16 | ||
2015-05-06 | 2015-03-31 | -0.08 | -0.09 | -0.01 | 12 | ||
2015-02-18 | 2014-12-31 | -0.14 | -0.14 | 0.0 | 0 | ||
2014-10-30 | 2014-09-30 | -0.15 | -0.19 | -0.04 | 26 | ||
2014-08-06 | 2014-06-30 | -0.44 | -0.57 | -0.13 | 29 | ||
2014-05-07 | 2014-03-31 | -0.53 | -0.62 | -0.09 | 16 | ||
2014-02-06 | 2013-12-31 | -0.38 | -0.46 | -0.08 | 21 | ||
2013-10-24 | 2013-09-30 | -0.79 | -0.44 | 0.35 | 44 | ||
2013-07-25 | 2013-06-30 | -0.46 | -0.37 | 0.09 | 19 | ||
2013-04-25 | 2013-03-31 | -0.38 | -0.38 | 0.0 | 0 | ||
2013-02-12 | 2012-12-31 | -0.41 | -0.33 | 0.08 | 19 | ||
2012-10-30 | 2012-09-30 | -0.39 | -0.37 | 0.02 | 5 | ||
2012-07-31 | 2012-06-30 | -0.43 | -0.42 | 0.01 | 2 | ||
2012-04-26 | 2012-03-31 | 0.84 | 0.93 | 0.09 | 10 | ||
2012-02-09 | 2011-12-31 | -0.39 | -0.45 | -0.06 | 15 | ||
2011-10-27 | 2011-09-30 | -0.33 | -0.37 | -0.04 | 12 | ||
2011-07-28 | 2011-06-30 | -0.28 | -0.31 | -0.03 | 10 | ||
2011-04-28 | 2011-03-31 | -0.28 | -0.28 | 0.0 | 0 | ||
2011-02-15 | 2010-12-31 | -0.28 | -0.25 | 0.03 | 10 | ||
2010-10-21 | 2010-09-30 | -0.27 | -0.29 | -0.02 | 7 | ||
2010-07-22 | 2010-06-30 | -0.28 | -0.28 | 0.0 | 0 | ||
2010-04-21 | 2010-03-31 | -0.29 | -0.35 | -0.06 | 20 | ||
2010-02-11 | 2009-12-31 | -0.33 | -0.35 | -0.02 | 6 | ||
2009-10-27 | 2009-09-30 | -0.34 | -0.35 | -0.01 | 2 | ||
2009-07-23 | 2009-06-30 | -0.35 | -0.35 | 0.0 | 0 | ||
2009-04-22 | 2009-03-31 | -0.32 | -0.31 | 0.01 | 3 | ||
2009-02-12 | 2008-12-31 | -0.36 | -0.26 | 0.1 | 27 | ||
2008-10-23 | 2008-09-30 | -0.35 | -0.34 | 0.01 | 2 | ||
2008-07-24 | 2008-06-30 | -0.49 | -0.44 | 0.05 | 10 | ||
2008-04-21 | 2008-03-31 | -0.48 | -0.49 | -0.01 | 2 | ||
2008-02-14 | 2007-12-31 | -0.55 | -0.54 | 0.01 | 1 | ||
2007-10-25 | 2007-09-30 | -0.63 | -0.53 | 0.1 | 15 | ||
2007-07-26 | 2007-06-30 | -0.68 | -0.75 | -0.07 | 10 | ||
2007-04-26 | 2007-03-31 | -0.67 | -0.82 | -0.15 | 22 | ||
2007-02-08 | 2006-12-31 | -0.64 | -0.63 | 0.01 | 1 | ||
2006-10-26 | 2006-09-30 | -0.63 | -0.63 | 0.0 | 0 | ||
2006-07-27 | 2006-06-30 | -0.75 | -0.7 | 0.05 | 6 | ||
2006-04-27 | 2006-03-31 | -0.69 | -0.86 | -0.17 | 24 | ||
2006-02-09 | 2005-12-31 | -0.7 | -0.79 | -0.09 | 12 | ||
2005-10-27 | 2005-09-30 | -0.6 | -0.71 | -0.11 | 18 | ||
2005-07-27 | 2005-06-30 | -0.61 | -0.6 | 0.01 | 1 | ||
2005-05-04 | 2005-03-31 | -0.56 | -0.59 | -0.03 | 5 | ||
2005-02-16 | 2004-12-31 | -0.45 | -0.56 | -0.11 | 24 |
Innoviva Corporate Management
| Pavel CFA | Chief Officer | Profile | |
| Patricia Drake | I Therapeutics | Profile | |
| Marianne CPA | Chief Secretary | Profile | |
| Stephen MBA | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innoviva. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Innoviva Stock refer to our How to Trade Innoviva Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innoviva. If investors know Innoviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innoviva listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.98) | Earnings Share 0.81 | Revenue Per Share | Quarterly Revenue Growth 0.331 | Return On Assets |
The market value of Innoviva is measured differently than its book value, which is the value of Innoviva that is recorded on the company's balance sheet. Investors also form their own opinion of Innoviva's value that differs from its market value or its book value, called intrinsic value, which is Innoviva's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innoviva's market value can be influenced by many factors that don't directly affect Innoviva's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innoviva's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innoviva is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innoviva's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.